In the following article by the Journal for Clinical Studies, Travis Caudill writes how the shift from large-scale, global clinical trials to focused orphan indication studies is impacting site feasibility.

In the following article by the Journal for Clinical Studies, Henry J. Riordan, Michael Murphy, Eric D Perakslis, and Sam Roosz discuss how to use large data sets and extended trial observations to close the Alzheimer’s real-world evidence gap.

Ready to chat about your real-world evidence program? Dr. Michael Murphy discusses real-world evidence and what happens after a clinical trial.

In this video, 3 experts share what makes the Worldwide Clinical Trials Early Phase Program, including the Bioanalytical Lab and Clinical Pharmacology Unit, different.

With so many regulations and so much confusion around biosimilars, it can often feel like patients have to choose between death or financial burden. Work with a CRO that can help you achieve the best biosimilar development program. Watch our latest webinar now to learn more.

In the following article by North Carolina Biotechnology Center, Dr. Elizabeth Witherspoon, NCBiotech Writer, discusses the strategic partnership between Worldwide and Deep Lens to utilize AI technology and develop a greater oncology focus in order to address rapidly changing trial needs.